Contineum Therapeutics (CTNM) reported late Monday dosing of the first cohort of patients in the PIPE-791 phase 1b positron emission tomography trial.

The study is expected to measure the correlation of pharmacokinetics to receptor occupancy by positron emission tomography imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients, it said.

Contineum said it expects topline data from the trial in Q2 2025.